Shanghai Fosun, TPB Capital To Buy Chindex, Take Hospital Chain Private
This article was originally published in PharmAsia News
Shanghai Fosun Phrmaceutical Group has joined with a private-equity firm to buy Chindex International, a China hospital chain, for $369 million.
You may also be interested in...
In this edition of the Device Week podcast, Medtech Insight managing editor Marion Webb discusses LifeSignals’ plans for a vital-sign monitoring patch that could help remotely monitor patients during the pandemic. Deputy editor Reed Miller highlights some important device trials presented at the American College of Cardiology online conference.
Following the announcement in the US that ranitidine drugs must be withdrawn from the market, the European Medicines Agency told the Pink Sheet it would decide on the fate of these medicines in the EU after wrapping up its own inquiry.
In addition to our daily in-depth coverage of key events relating to the COVID-19 pandemic, we’re bringing you a periodic round-up of other developments. This edition covers Europe and other countries.